Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ontamalimab in NASH with Fibrosis
NCT07052682Phase 1Terminated
- Sponsor
- Takeda
- Start
- Jan 2023
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ontamalimab in Nonalcoholic steatohepatitis (NASH), sponsored by Takeda. Primary endpoints: Number of Participants With Treatment-emergent Adverse Events at Week 36, Number of Participants With Clinically Significant Abnormalities in Clinical Laboratory Values at Week 36 and 3 more. Started Jan 2023; status: terminated.
02
Drugs
ontamalimab
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT07052682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07052682.